To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study / Baeten, D., Østergaard, M., Wei, J.C., Sieper, J., Järvinen, P., Tam, L., Salvarani, C., Kim, T., Solinger, A., Datsenko, Y., Pamulapati, C., Visvanathan, S., Hall, D.B., Aslanyan, S., Scholl, P., Padula, S.J.. - In: ANNALS OF THE RHEUMATIC DISEASES. THE EULAR JOURNAL. - ISSN 1792-328X. - 77:9(2018), pp. 1295-1302. [10.1136/annrheumdis-2018-213328]
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Salvarani, Carlo;
2018
Abstract
To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).
| File | Dimensione | Formato | |
|---|---|---|---|
|
1295.full.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Licenza:
[IR] creative-commons
Dimensione
1.3 MB
Formato
Adobe PDF
|
1.3 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
